Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Saxony-Anhalt Embraces Change as an Opportunity: Billions Invested in Key Transformation Industries

Published

on

saxony-anhalt-embraces-change-as-an-opportunity:-billions-invested-in-key-transformation-industries

Companies are currently injecting nearly three billion euros into projects in Saxony-Anhalt, marking a significant commitment to transformative initiatives. When factoring in Intel’s giga-investments, an additional zero needs to be appended.

MAGDEBURG, Germany, Feb. 26, 2024 /PRNewswire/ — The largest investment project not only in Saxony-Anhalt but in all of Europe is Intel‘s establishment in Magdeburg. Approximately 30 billion euros are set to be invested in the construction of multiple chip factories. The company has initiated collaborations with six universities in Saxony-Anhalt and is actively recruiting its initial workforce. Approval processes commenced in February, paving the way for the production of the world’s most advanced chips in the two factories starting from 2027.

 

 

In addition to Intel, numerous other semiconductor companies are also making substantial investments. Sioux Technologies, a globally recognized technology accelerator with around 1,100 employees, is developing strategic high-tech solutions for various markets such as semiconductors, laboratory and medical technology, mechatronics, imaging, mobility, and clean energy. In Barleben, Sioux plans to invest around 20 million euros in a research and development center, gradually creating three hundred highly qualified permanent jobs.

Meanwhile, in Bernburg, a large high-performance distribution center for semiconductors and electronic components is taking shape. The topping-out ceremony for Avnet’s Electronics Distribution Center was celebrated in November 2023, with an investment volume exceeding 225 million euros. Over the next eight years, around 700 jobs are expected to be created in Bernburg.

Sven Schulze, Minister for Economic Affairs, Tourism, Agriculture, and Forestry of the State of Saxony-Anhalt, emphasizes the economic dynamism of the region against the backdrop of these examples: “Saxony-Anhalt is on the fast track. High-profile fast-track approvals, a central location in Europe, close collaboration with educational institutions, and attractive conditions such as affordable rents and sufficient childcare spaces make investments and living here exceptionally appealing.”

Life Sciences Take Pioneering Role in Saxony-Anhalt’s Future

Saxony-Anhalt is establishing itself as a leader in the field of Life Sciences, showcasing the state’s future resilience. The mRNA Center in Halle (Saale) is taking shape, with the Wacker Chemie AG demonstrating serious ambitions in this cutting-edge technology through a substantial investment exceeding 100 million euros. The new facility is expected to host around 200 employees. Additionally, the Magdeburg-based medical technology company Neoscan Solutions recently secured a contract to build the world’s most powerful 14 Tesla MRI magnet for human examinations.

Chemical parks in Saxony-Anhalt are undergoing expansion and sustainable transformation, with Germany’s largest Chemical Park Leuna, being one of the nation’s largest construction sites. Over 100 companies from eleven nations are investing 1.3 billion euros in research and green chemistry. The expansion is set to create up to 250 direct and 750 indirect jobs, primarily in the sustainable chemistry sector. AMG Lithium has chosen the Chemical Park Bitterfeld-Wolfen for a 140-million-euro investment to purify lithium hydroxide, transforming it into a battery-grade raw material – a unique endeavor in Europe.

Innovations in renewables and storage technologies

NexWafe, a US-based company, is investing 30 million euros in Bitterfeld-Wolfen to establish a factory for producing solar wafers, a crucial material for the photovoltaic industry. In Bitterfeld, the German company Silicon Products, in collaboration with a French partner, aims to produce high-purity silicon carbide, a vital resource for nearly all semiconductor manufacturers.

TESVOLT AG, a leading technology company in commercial and industrial energy storage, plans to construct a new Gigafactory in Lutherstadt Wittenberg, investing around 60 million euros. The long-term goal is to create over 400 new jobs, particularly in research and development.

The automotive and logistics sectors are also experiencing rapid development from international players. LMG Manufacturing, an aluminum die-casting specialist, inaugurated its new manufacturing hall in Hoym/Seeland after just ten months of construction. Daimler Truck‘s largest logistics project commenced with the official groundbreaking in Halberstadt in September 2023. The Global Parts Center in Halberstadt/Harz aims to deliver spare parts worldwide starting in 2025, generating approximately 450 jobs with an investment of nearly 500 million euros.

Dr. Robert Franke, Managing Director of the Investment and Marketing Corporation Saxony-Anhalt mbH, emphasizes, “Saxony-Anhalt is an attractive and sought-after location for settlement. We are witnessing significant investments not only in the chip industry but also in various other sectors such as pharmaceuticals, medical technology, and the automotive industry. This underscores why Saxony-Anhalt has gained considerable international visibility.”

Read more details here.

CONTACT: Sabine Kraus, +49 391/568 9920, [email protected] 

Video – https://www.youtube.com/watch?v=_cNaOTqHjgk
Logo –  https://mma.prnewswire.com/media/1840465/4556227/IMG_Sachsen_Anhalt_Logo.jpg

 

IMG Sachsen Anhalt Logo

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/saxony-anhalt-embraces-change-as-an-opportunity-billions-invested-in-key-transformation-industries-302068763.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading

Trending